Abstract #1041607: Effects of Prior Injectable Somatostatin Receptor Ligand Type and Dose in Patients With Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial

MLA

Nienke R. Biermasz, et al. “Abstract #1041607: Effects of Prior Injectable Somatostatin Receptor Ligand Type and Dose in Patients With Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial.” Endocrine Practice, vol. 27, June 2021, p. S131. EBSCOhost, https://doi.org/10.1016/j.eprac.2021.04.745.

APA

Nienke R. Biermasz, Irina Bondar, Mark E. Molitch, Djuro P Macut, Asi Haviv, Elena Isaeva, Shlomo Melmed, Yulia Pokramovich, Alexander Dreval, Maria Fleseriu, Christian J. Strasburger, Murray B. Gordon, William H. Ludlam, Yossi Gilgun-Sherki, & Gary Patou. (2021). Abstract #1041607: Effects of Prior Injectable Somatostatin Receptor Ligand Type and Dose in Patients With Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial. Endocrine Practice, 27, S131. https://doi.org/10.1016/j.eprac.2021.04.745

Chicago

Nienke R. Biermasz, Irina Bondar, Mark E. Molitch, Djuro P Macut, Asi Haviv, Elena Isaeva, Shlomo Melmed, et al. 2021. “Abstract #1041607: Effects of Prior Injectable Somatostatin Receptor Ligand Type and Dose in Patients With Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial.” Endocrine Practice 27 (June): S131. doi:10.1016/j.eprac.2021.04.745.